ID

4471

Description

A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer Inclusion Criteria: - Diagnosis of prostate cancer. - Rising PSA while on hormonal therapy or following surgical castration. - Documented evidence of metastatic disease. Exclusion Criteria: - Have received cytotoxic chemotherapy. - Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months

Keywords

  1. 12/9/13 12/9/13 - Martin Dugas
Uploaded on

December 9, 2013

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0 Legacy

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility DRKS00009647 NCT00036543 Prostate Cancer

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion criteria
Description

Inclusion criteria

Diagnosis of prostate cancer
Description

Diagnosis

Data type

boolean

Rising PSA while on hormonal therapy or following surgical castration
Description

PSA

Data type

boolean

Documented evidence of metastatic disease
Description

Metastasis

Data type

boolean

Exclusion criteria
Description

Exclusion criteria

Have received cytotoxic chemotherapy
Description

Chemotherapy

Data type

boolean

Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months
Description

Pain by Prostate Cancer

Data type

boolean

Medical Concepts
Description

Medical Concepts

Diagnosis
Description

Diagnosis

Data type

string

Alias
UMLS CUI
C0011900
SNOMED CT 2010_0731
439401001
PSA
Description

Prostate-Specific Antigen

Data type

string

Alias
UMLS CUI
C0138741
SNOMED CT 2010_0731
102687007
Metastatic malignant disease
Description

Secondary malignant neoplastic disease

Data type

string

Alias
UMLS CUI
C0027627
SNOMED CT 2010_0731
128462008
Cancer chemotherapy
Description

Chemotherapy

Data type

string

Alias
UMLS CUI
C0392920
SNOMED CT 2010_0731
150415003
Medication
Description

Pharmaceutical Preparations

Data type

string

Alias
UMLS CUI
C0013227
Radiotherapy
Description

Radiotherapy

Data type

string

Alias
UMLS CUI
C1522449
SNOMED CT 2010_0731
302505005

Similar models

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion criteria
Diagnosis
Item
Diagnosis of prostate cancer
boolean
PSA
Item
Rising PSA while on hormonal therapy or following surgical castration
boolean
Metastasis
Item
Documented evidence of metastatic disease
boolean
Item Group
Exclusion criteria
Chemotherapy
Item
Have received cytotoxic chemotherapy
boolean
Pain by Prostate Cancer
Item
Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months
boolean
Item Group
Medical Concepts
Diagnosis
Item
Diagnosis
string
C0011900 (UMLS CUI)
439401001 (SNOMED CT 2010_0731)
Prostate-Specific Antigen
Item
PSA
string
C0138741 (UMLS CUI)
102687007 (SNOMED CT 2010_0731)
Secondary malignant neoplastic disease
Item
Metastatic malignant disease
string
C0027627 (UMLS CUI)
128462008 (SNOMED CT 2010_0731)
Chemotherapy
Item
Cancer chemotherapy
string
C0392920 (UMLS CUI)
150415003 (SNOMED CT 2010_0731)
Pharmaceutical Preparations
Item
Medication
string
C0013227 (UMLS CUI)
Radiotherapy
Item
Radiotherapy
string
C1522449 (UMLS CUI)
302505005 (SNOMED CT 2010_0731)

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial